Options traders at Cellebrite DI are more defensive than at any point in recent months — and a new buy rating filed this week has done little to reverse the week's losses.
The sharpest signal this week is in the options market. The put/call ratio has jumped to 0.37, more than two standard deviations above its 20-day average of 0.31. That's the most defensive reading in at least a year, just a notch below the 52-week high of 0.43, and it landed alongside a 4.2% price drop on the week to $12.89. Options traders are paying noticeably more attention to downside protection than they have throughout most of the past year.
Short interest tells a much calmer story and doesn't belong at the centre of this note. At 1.6% of the free float, the short position is modest and falling — down roughly 17% over the past month. Borrowing the stock costs almost nothing at 0.38% annualised, and borrow availability is extremely loose at around 2,100%, meaning there are more than twenty shares available to borrow for every one already shorted. The lending market offers no squeeze dynamic here.
The Street is firmly bullish in direction, though recent moves suggest patience is wearing thin. DA Davidson initiated coverage this week with a Buy and a $20 target — more than 55% above the current price. That contrasts with Needham, which maintained its Buy on May 15 but trimmed its target to $15 from $18, citing post-earnings caution. The mean analyst target across five covering analysts is $21, a gap that underlines just how wide the disconnect is between where the Street thinks CLBT belongs and where it actually trades. The bull case rests on 21% ARR growth to $493M in Q1 2026, a 23.9% EBITDA margin, and deepening AI integration across its digital investigative platform. Bears point to concentration risk in government budgets, early-termination exposure, and uncertainty around recent acquisitions of SCG Canada and Corellium.
Institutional flows add a nuanced layer. Voss Capital added 1.6 million shares in Q1, Pertento Partners built a new position of 703,000 shares, and Brown Capital Management entered the register with 2.7 million shares — all in the March quarter. Against that, Capital Research trimmed by nearly 1.9 million shares. On the insider side, activity over the past month has been routine sell transactions from the Chief Marketing Officer and a Chief Level Officer, totalling less than $250,000 net over 90 days. The significance scores on all of these trades were minimal, and the seller pattern is consistent with vesting-related disposal rather than any strategic exit.
The most recent earnings print, on May 14, sent the stock up 7.3% on the day and 8.8% over the following week — a clean positive reaction that has since been almost entirely given back. The next event is scheduled for August 13. Between now and then, the key question is whether the ARR growth narrative can hold against any softness in government spending commitments, and whether DA Davidson's fresh initiation draws incremental institutional interest into a float that already has plenty of room to absorb new short positions — but clearly isn't drawing them.
See the live data behind this article on ORTEX.
Open CLBT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
